Association of the CYP1B1 Leu432Val polymorphism with the risk of prostate cancer: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 7, 2012, Pages 7465-7471

  Cui, Lingling ^a,b   Dillehay, Kelsey ^b   Chen, Weimin ^b   Shen, Deliang ^c   Dong, Zhongyun ^b   Li, Wenjie ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

CYP1B1; Meta analysis; Polymorphism; Prostate cancer; Susceptibility

Indexed keywords

CYTOCHROME P450 1B1; LEUCINE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; CYP1B1 GENE; DATA ANALYSIS; ETHNIC DIFFERENCE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; QUANTITATIVE STUDY; SYSTEMATIC REVIEW;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84864285476     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1579-y     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59(4):225-249.10.3322/caac.20006
2. Gsur A, Feik E, Madersbacher S (2004) Genetic polymorphisms and prostate cancer risk. World J Urol 21(6):414-423. doi:10.1007/s00345-003-0378-4
3. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI (1999) Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett 139(2):199-205 (Pubitemid 29225121)
4. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Gu-engerich FP, Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56(13):2979-2984 (Pubitemid 26199741)
5. Agundez JA (2004) Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 5(3):211-224 (Pubitemid 38735776)
6. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62(3):573-584. doi:10.1086/301764 (Pubitemid 28164614)
7. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20(8): 1607-1613 (Pubitemid 29385452)
8. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60(13):3440-3444 (Pubitemid 30482162)
9. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T (2000) Polymorphisms in P450 CYP1B1 affect the conversion of estra-diol to the potentially carcinogenic metabolite 4-hydroxyestra-diol. Pharmacogenetics 10(4):343-353 (Pubitemid 30345182)
10. Landi MT, Bergen AW, Baccarelli A, Patterson DG Jr, Grassman J, Ter-Minassian M, Mocarelli P, Caporaso N, Masten SA, Pes-atori AC, Pittman GS, Bell DA (2005) CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology 207(2):191-202. doi: 10.1016/j.tox.2004.08.021 (Pubitemid 39642835)
11. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF (2000) Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10(9):761-766 (Pubitemid 32042828)
12. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296(4):820-826
13. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J (2003) Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 89(8):1524-1529. doi:10.1038/sj.bjc.6601288 (Pubitemid 37386610)
14. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, Ichikawa T, Tsukino H, Qiu D, Katoh T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24(4):2431-2437 (Pubitemid 39166328)
15. Cicek MS, Liu X, Casey G, Witte JS (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Bio-markers Prev 14(9):2173-2177. doi:10.1158/1055-9965.EPI-05-0215 (Pubitemid 41603264)
16. Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H (2006) CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 25(5):287-294 (Pubitemid 43830442)
17. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, Hayes RB (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(1):165-168. doi:10.1158/1055-9965.EPI-06-0689 (Pubitemid 46174281)
18. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25(24):3596-3602. doi:10.1200/JCO. 2007.11.0908 (Pubitemid 47376605)
19. Beuten J, Gelfond JAL, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ (2008) CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis 29(9):1751-1757. doi:10.1093/carcin/bgm300
20. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719-748
21. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer SJ, Casey G, Witte JS (2006) Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 27(9):1842-1848. doi:10.1093/carcin/bgl022 (Pubitemid 44288666)
22. Beuten J, Gelfond JAL, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ (2009) Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 18(6):1869-1880. doi: 10.1158/1055-9965.Epi-09-0076
23. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A (2008) Association of the CYP1B13 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 7(1):19-26. doi:10.1158/1535-7163.MCT-07-0557
24. Nock NL, Tang DL, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Monaghan KG, Koprowski A, Mitrache N, Yang JJ, Rybicki BA (2007) Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev 16(6):1236-1245. doi: 10.1158/1055-9965.Epi-06-0736 (Pubitemid 46984965)
25. Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R (2010) Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-resistant prostate cancer (CRPC) patients. BMC Cancer 10:511. doi:10.1186/1471-2407-10-511
26. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16(5):969-978. doi:10.1158/1055-9965.EPI-06-0767 (Pubitemid 46910099)
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi:10.1136/bmj.327.7414. 557 (Pubitemid 37088507)
28. Wang F, Zou YF, Sun GP, Su H, Huang F (2011) Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis. Eur J Cancer Prev 20(2):112-120. doi: 10.1097/CEJ.0b013e3283410193
29. Chen B, Qiu LX, Li Y, Xu W, Wang XL, Zhao WH, Wu JQ (2010) The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 70(3):247-252. doi:10.1016/j.lungcan.2010.03.011
30. Yao L, Fang F, Wu Q, Zhong Y, Yu L (2010) No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40, 303 subjects. Breast Cancer Res Treat 122(1):237-242. doi:10.1007/s10549-009-0689-2
31. Xie Y, Liu GQ, Miao XY, Liu Y, Zhou W, Zhong DW (2011) CYP1B1 Leu432Val polymorphism and colorectal cancer risk among Caucasians: a meta-analysis. Tumour Biol. doi:10.1007/s13277-011-0298-7
32. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG (2002) Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyest-radiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23(2):329-333 (Pubitemid 34224011)
33. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawa-kami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R (2005) Cytochrome P450 1B1 is over-expressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 11(16):5793-5801. doi:10.1158/1078-0432. CCR-04-2545 (Pubitemid 41170305)
34. Lee J, Demissie K, Lu SE, Rhoads GG (2007) Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 14(1):78-85 (Pubitemid 46172395)